BioNTech
NEWS
Despite having infinitely better global communications, exact figures are hard to come by for COVID-19 fatalities. Here’s a look at that story and more COVID-19 news.
Context Therapeutics’ lead candidate ONA-XR prevents interaction between progesterone and its receptor, downregulates cancer stem cell mobilization and blocks immune evasion.
Three long-time FDA officials, Dr. Peter Marks, Dr. Janet Woodcock and Dr. Robert Califf wrote an op-ed in JAMA describing the reality that COVID-19 represents “the new normal.”
Pfizer reported first-quarter revenues of $25.7 billion, a whopping 82% operational growth. This growth was largely driven by its COVID-19 vaccine developed with BioNTech and its antiviral drug, Paxlovid.
Moderna is poised to seek the regulatory authorization of its COVID-19 vaccine in children between six months and 5 years.
Ocugen has amended its co-development, supply and commercialization deal with Bharat to include Mexico and now holds the rights for the Covaxin vaccine for all of North America.
It was a very busy week for clinical trial news, with much of it coming out of the American Association of Cancer Research Annual Meeting. Read on for details.
Pfizer and BioNTech will submit updated data to the FDA to support the Emergency Use Authorization (EUA) of COVID-19 vaccination boosters in children between the age of 5 and 11.
The week began with new partnerships formed in the life sciences industry as several firms entered into licensing deals and collaboration commitments. Here’s a look at the latest.
JOBS
IN THE PRESS